The Phase 2 LiBBY trial (Life's End Benefits of cannaBidiol and tetrahYdrocannabinol) tested purified THC/CBD oil for late-stage agitation. People with mild cognitive impairment — noticeable change with daily independence kept — were not studied and gain no treatment signal from it.
LiBBY reported first topline results at AAIC 2026 on July 14, according to the LiBBY Study in its official results announcement. The study focused on comfort at life's end, not on slowing early decline. That focus decides how to read every number that followed.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who was actually studied?
- What improved, and what raised concern?
- Why does this not apply to mild cognitive impairment?
- What should you do after seeing the headline?
Who was actually studied?
LiBBY enrolled 120 people with advanced Alzheimer's or other dementias. All were hospice-eligible or receiving hospice care and had clinically significant agitation. NeurologyLive reported this frail group has been historically excluded from dementia trials.
Participants received placebo or T2:C100, a mix of 2 mg THC plus 100 mg CBD in digestible oil twice daily. Staff gave it during home or residence visits across 10 U.S. sites. Treatment lasted 12 weeks.
What improved, and what raised concern?
Agitation scores fell more with THC/CBD at week 2, as Vision Monday staff reported in their AAIC presentation report. The mean gap on the Cohen-Mansfield Agitation Inventory, a standard agitation checklist, was -6.27 points. The 95% interval ran from -9.66 to -2.87, with p=0.0004. Benefit held to week 12 with sustained separation on the same checklist.
Global improvement reached 83.9% at week 2 and 87.2% at week 12, versus 30.5% and 23.6% on placebo, according to NeurologyLive in its summary. Those ratings reflect overall impression of change. NeurologyLive reported similar overall treatment-emergent events between groups. Serious events were higher with THC/CBD at 23.3% versus 11.9%, driven by serious infections at 11.7% versus 1.7%. Deaths were higher at 13.1% versus 5.1% in this frail end-of-life group.
Why does this not apply to mild cognitive impairment?
Mild cognitive impairment means noticeable cognitive change with independence kept in most daily tasks. The Alzheimer's Association describes that early stage as distinct from major neurocognitive disorder, as explained on its MCI definition page. LiBBY studied hospice-level dementia, not this earlier stage.
LiBBY investigators limit the finding to that purified dose and oil system used under supervision. The result does not carry over to dispensary, over-the-counter, or other cannabis products. Strength, content, and monitoring differ outside the trial.
- LiBBY group: advanced dementia, hospice care, severe agitation
- MCI group: noticeable change, daily independence kept
- LiBBY product: purified 2 mg THC plus 100 mg CBD oil, supervised
- Store product: varied content, no trial supervision
What should you do after seeing the headline?
Do not try a cannabis oil to protect memory or ease worry. The trial gives no dose, safety record, or benefit for MCI. Bring the headline to your clinician and ask what it changes for you.
Use the visit to clarify your own stage and plan. Tracking recent examples helps more than quoting the trial. Bring a one-page note with two or three examples from the past month.
- list medicines, sleep changes, mood changes, and harder daily tasks
- note when lapses happen and what helps in the moment
- ask about hearing, sleep, mood, and medicines that affect thinking
- set a date to recheck thinking and daily function
You Might Also Like
- Electronic Health Records for Dementia Care Research in 2026: How People With Mild Cognitive Impairment Can Avoid Overreading the Headline
- Implementation-Ready Dementia Interventions in the 2026 NIA Report: Questions People With Mild Cognitive Impairment Can Ask About the Research
- Implementation-Ready Dementia Interventions in the 2026 NIA Report: Questions People With Mild Cognitive Impairment Can Ask About the Research
